STAAR SURGICAL CO
Business
STAAR Surgical Company designs, manufactures, and sells implantable collamer lenses (ICLs) for refractive eye surgery, positioning itself as the global leader in phakic lens implants. The company offers the EVO family of ICLs to treat myopia, hyperopia, and astigmatism, along with delivery systems and accessory products. STAAR operates through a single reportable segment and distributes directly in select countries and through independent distributors in numerous countries worldwide, with the substantial majority of revenue from international markets.
Summary from 10-K filed 2026-03-03
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net sales | 239 | 314 | 322 | 239 | 230 | |
| Cost of sales | 57 | 74 | 70 | 61 | 52 | |
| Gross profit | 182 | 240 | 253 | 223 | 179 | |
| General and administrative | 86 | 90 | 72 | 55 | 44 | |
| Selling and marketing | 103 | 117 | 112 | 89 | 67 | |
| Research and development | 40 | 45 | 40 | 36 | 34 | |
| Merger transaction and related costs | 17 | — | — | — | — | |
| Restructuring, impairment and related charges | 29 | — | — | — | — | |
| Total selling, general and administrative expenses | 274 | 252 | 225 | 180 | 145 | |
| Operating income (loss) | −92 | −13 | 28 | 44 | 33 | |
| Interest income, net | 5 | 6 | 7 | 2 | −38,000 | |
| Gain (loss) on foreign currency transactions | 3 | −4 | −2 | −2 | −3 | |
| Royalty income | — | 508,000 | 74,000 | 804,000 | 1 | |
| Other income, net | 2 | 815,000 | 448,000 | 205,000 | −48,000 | |
| Total other income, net | 9 | 4 | 6 | 2 | −2 | |
| Income (loss) before income taxes | −82 | −9 | 34 | 46 | 31 | |
| Provision (benefit) for income taxes | −2 | 11 | 12 | 6 | 4 | |
| Net income (loss) | −80 | −20 | 21 | 40 | 28 | |
| Basic (per share) | −1.62 | −0.41 | 0.44 | 0.83 | 0.58 | |
| Diluted (per share) | −1.62 | −0.41 | 0.43 | 0.8 | 0.56 | |
| Basic (shares) | 50 | 49 | 49 | 48 | 47 | |
| Diluted (shares) | 50 | 49 | 49 | 49 | 49 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 153 | 144 | 183 | 86 | 200 | |
| Investments available for sale (amortized cost basis of $34,385 and $86,346 at January 2, 2026 and December 27, 2024, respectively) | 34 | 86 | 38 | 125 | — | |
| Accounts receivable trade, net of allowance for credit losses of $83 and $32 at January 2, 2026 and December 27, 2024, respectively | 50 | 78 | 95 | 62 | 44 | |
| Inventories, net | 55 | 43 | 35 | 24 | 17 | |
| Prepayments, deposits and other current assets | 18 | 16 | 15 | 13 | 11 | |
| Total current assets | 312 | 368 | 365 | 312 | 271 | |
| Property, plant and equipment, net | 73 | 85 | 67 | 51 | 36 | |
| Finance lease right-of-use assets, net | — | 37,000 | 183,000 | 342,000 | 506,000 | |
| Operating lease right-of-use assets, net | 30 | 37 | 34 | 34 | 31 | |
| Cloud-based software | 31 | 16 | — | — | — | |
| Goodwill | 2 | 2 | 2 | 2 | 2 | |
| Deferred income taxes | 3 | 788,000 | 5 | 9 | 4 | |
| Other assets | 1 | 1 | 3 | 957,000 | 822,000 | |
| Total assets | 452 | 510 | 489 | 419 | 346 | |
| Accounts payable | 12 | 17 | 14 | 12 | 9 | |
| Obligations under finance leases | — | 42,000 | 165,000 | 169,000 | 127,000 | |
| Obligations under operating leases | 6 | 4 | 4 | 4 | 3 | |
| Allowance for sales returns | 10 | 7 | 6 | 6 | 5 | |
| Other current liabilities | 41 | 43 | 41 | 31 | 32 | |
| Total current liabilities | 69 | 70 | 65 | 52 | 49 | |
| Obligations under operating leases | 32 | 35 | 31 | 27 | 28 | |
| Deferred income taxes | — | 297,000 | 1 | 1 | 811,000 | |
| Asset retirement obligations | 45,000 | 42,000 | 103,000 | 220,000 | 198,000 | |
| Deferred rent | 89,000 | — | — | — | — | |
| Pension liability | 6 | 7 | 5 | 2 | 9 | |
| Total liabilities | 107 | 112 | 103 | 83 | 87 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock, $0.01 par value; 60,000 shares authorized: 49,779 shares issued and 49,403 shares outstanding at January 2, 2026 and 49,294 shares issued and outstanding at December 27, 2024, respectively | 498,000 | 493,000 | 488,000 | 482,000 | 477,000 | |
| Additional paid-in capital | 505 | 471 | 437 | 404 | 374 | |
| Treasury stock, 376 and 0 shares at January 2, 2026 and December 27, 2024, respectively | −6 | — | — | — | — | |
| Accumulated other comprehensive loss | −7 | −7 | −4 | 156,000 | −4 | |
| Accumulated deficit | −148 | −68 | −47 | −69 | −111 | |
| Total stockholders equity | 344 | 397 | 386 | 336 | 262 | |
| Total liabilities and stockholders equity | 452 | 510 | 489 | 419 | 346 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation of property, plant, and equipment | 8 | 7 | 5 | 4 | 4 | |
| Amortization of cloud-based software | 409,000 | — | — | — | — | |
| Non-cash operating lease expense | 4 | 4 | 3 | — | — | |
| Impairment of fixed assets and operating lease right-of-use assets | 15 | — | — | — | — | |
| Gain on fixed asset recovery | −1 | — | — | — | — | |
| Amortization of intangibles | — | — | 13,000 | 28,000 | 34,000 | |
| Impairment of intangibles | — | — | 154,000 | — | — | |
| Accretion/amortization of investments available for sale | −198,000 | −1 | −3 | −1 | — | |
| Deferred income taxes | −3 | 4 | 3 | −2 | −2 | |
| Change in net pension liability | −249,000 | 26,000 | −956,000 | 53,000 | 137,000 | |
| Loss on disposal of property and equipment | 74,000 | 2 | 73,000 | 65,000 | 2,000 | |
| Stock-based compensation expense | 31 | 27 | 24 | 20 | 15 | |
| Change in asset retirement obligation | 4,000 | −53,000 | −102,000 | 47,000 | — | |
| Provision for sales returns and credit losses | 4 | 286,000 | 663,000 | 913,000 | 318,000 | |
| Inventory provision | 5 | 3 | 5 | 2 | 2 | |
| Accounts receivable | 28 | 16 | −33 | −20 | −9 | |
| Inventories | −17 | −10 | −14 | −8 | 66,000 | |
| Prepayments, deposits, and other assets | −1 | −2 | −1 | −3 | −711,000 | |
| Cloud-based software | −16 | −13 | −2 | — | — | |
| Accounts payable | −6 | 75,000 | −701,000 | 2 | 108,000 | |
| Other current liabilities and non-currnet liabilities | −5 | −169,000 | 7 | — | — | |
| Net cash provided by (used in) operating activities | −34 | 16 | 15 | 36 | 44 | |
| Acquisition of property and equipment | −6 | −23 | −18 | −18 | −14 | |
| Purchase of investments available for sale | −75 | −80 | −52 | −156 | — | |
| Proceeds from maturity of investments available for sale | 124 | 43 | 144 | 17 | — | |
| Proceeds from sale of investments available for sale | 3 | 1 | 1 | 359,000 | — | |
| Net cash provided by (used in) investing activities | 46 | −59 | 74 | −156 | −14 | |
| Repayment of finance lease obligations | −42,000 | −165,000 | −161,000 | −126,000 | −348,000 | |
| Repurchase of common stock | −6 | — | — | — | — | |
| Repurchase of employee common stock for taxes withheld | −2 | −2 | −2 | — | — | |
| Proceeds from the exercise of stock options | 3 | 7 | 10 | 8 | 19 | |
| Proceeds from vested restricted and performance stock units | 3,000 | 2,000 | 1,000 | — | — | |
| Net cash provided by (used in) financing activities | −5 | 6 | 7 | 8 | 18 | |
| Effect of exchange rate changes on cash and cash equivalents | 1 | −1 | 202,000 | −862,000 | −857,000 | |
| Increase (decrease) in cash and cash equivalents | 9 | −39 | 97 | −113 | 47 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is STAAR SURGICAL CO's CIK number?
STAAR SURGICAL CO's SEC CIK number is 0000718937 (718937). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find STAAR SURGICAL CO's SEC filings?
All of STAAR SURGICAL CO's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did STAAR SURGICAL CO last report earnings?
STAAR SURGICAL CO (STAA) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000718937-26-000022). This is STAAR SURGICAL CO's most recent earnings filing of record — not a forecast of its next earnings date.
What is STAAR SURGICAL CO's most recent earnings 8-K?
STAAR SURGICAL CO's latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0000718937-26-000022. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View STAAR SURGICAL CO's latest earnings 8-K →
Look up any company's CIK number →